Format

Send to

Choose Destination
Methods Mol Med. 2001;66:289-304. doi: 10.1385/1-59259-148-5:289.

Serogroup B and C serum bactericidal assays.

Author information

1
Manchester Public Health Laboratory, Withington Hospital, Manchester, UK.

Abstract

Meningococci are usually classified based on serological reactivity of their polysaccharide capsules with serogroups A, B, and C, currently the most common causes of disease. Serogroup A meningococci can cause massive outbreaks particularly in areas such as the African meningitis belt, whereas other areas such as in the Americas and Europe, serogroups B and C predominate. Although licensed vaccines for serogroups A and C exist, based on the polysaccharide capsules, no such vaccine exists thus far for serogroup B owing to its poor immunogenicity in humans. This chapter discusses and details serum bactericidal assay protocols for measuring the complement-mediated lysis of serogroups B and C meningococci by human sera following vaccination or disease.

PMID:
21336762
DOI:
10.1385/1-59259-148-5:289

Supplemental Content

Loading ...
Support Center